Jennison Associates
ALNY icon

Jennison Associates’s Alnylam Pharmaceuticals ALNY Stock Holding History

Jennison Associates’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-166,300
Closed -$13M – 720
2014
Q3 		$13M Hold
166,300
– – 0.01% 468
2014
Q2 		$10.5M Hold
166,300
– – 0.01% 476
2014
Q1 		$11.2M Buy
+166,300
New +$12.9M 0.01% 485

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates's ALNY Position: Q1 2026 in Review

Jennison Associates sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 277,759 shares — an estimated $110M sold.

Jennison Associates first reported a position in ALNY in Q2 2013 and held it in 19 quarters. The position peaked at $140M in Q4 2015. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Jennison Associates reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Jennison Associates sold 277,759 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $110M.
  • Jennison Associates first reported a position in Alnylam Pharmaceuticals in Q2 2013 and held it in 19 quarters.
  • Jennison Associates's Alnylam Pharmaceuticals position peaked at $140M in Q4 2015.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Jennison Associates's 13F filing for Q1 2026, filed 6 May 2026.